Navigation Links
ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb
Date:10/30/2010

irus at week 4 (defined as Rapid Virological Response, or RVR). Patients are being followed for 24 weeks after stopping therapy to determine the rate of Sustained Virological Response, or SVR. Approximately 90 patients have been enrolled in this study – with approximately 30 patients receiving ANA598 plus SOC at each dose level and 30 patients receiving placebo plus SOC. The study is being managed by the Duke Clinical Research Institute (DCRI) and is being conducted at a number of clinical sites in the United States.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. Anadys is preparing to initiate a Phase IIb study of ANA598, the Company's direct-acting antiviral or DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) the plans and trial design for the planned ANA598 Phase IIb study; (ii) the belief that the preclinical properties of ANA598 support investigation of combinations with other direct antivirals and the ability to pursue such combinations;  (iii) assessments of the potency, safety and tolerability profile of ANA598 based on the 12 week results; (iv) the durability of antiviral response after treatment with ANA598 is conc
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
11. ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... MUMBAI, India , September 17, 2014 ... TRPA1 antagonist, GRC 17536, has shown positive data in ... with painful diabetic neuropathy , ... Transient Receptor Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 ... blind, placebo controlled, multi-centre, proof of concept study conducted ...
(Date:9/17/2014)... Texas , Sept. 17, 2014  Lightbeam ... Direct Accountable Care Organization (Physician Direct ACO) to ... their physicians in providing better care while reducing ... Physician Direct Accountable Care Organization ... Network Services (OPNS). The OPNS mission is to ...
(Date:9/17/2014)... 2014 According to a new ... Battery, Memory Device, Display, & Microprocessor/MCU), by Application (Imaging, ... by Geography - Global Forecast to 2020", published by ... expected to reach $56.50 Billion by 2020, growing at ... Browse 235 market data Tables and 71 Figures ...
Breaking Medicine Technology:Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 North ... were recently granted several awards for their top-notch services. ... patient experience, orthopedic care and GYN surgery. , Hospital-wide, ... Safety Excellence Award™. They have received this award for ... among the top 5 percent in the nation for ...
(Date:9/17/2014)... News) -- A blood test that measures DNA from ... better assessment of the state of a man,s disease, ... this blood test could reveal when treatment for ... tumor growth, the researchers suggested. "Our study showed ... prostate cancer and often initially very effective started to ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Wright ... Conserve line of metal-on-metal hip replacements continue to ... U.S. District Court, Northern District of Georgia, Bernstein ... List issued by the U.S. Judicial Panel on ... 397 product liability claims have been filed in ...
(Date:9/17/2014)... are Asian Americans at higher risk of developing type ... the disease at lower body weights? One part of ... high-fiber, low-fat Asian diets to current westernized diets, which ... says George King, M.D., Senior Vice President and Chief ... author of the study. , A Joslin randomized clinical ...
(Date:9/17/2014)... London, UK (PRWEB) September 17, 2014 ... of the total medical technology market, focusing on molecular ... cancer, chronic diseases, and genetic testing. The IVD market ... billion by the end of 2017. The major drivers ... testing; need for speed, which is evidenced by the ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
... study of its kind, scientists from Toronto,s Centre for Addiction and ... a higher risk of developing schizophrenia. This finding was based on ... to a group that did not use drugs, but also to ... published online on Nov. 8, 2011, at AJP in ...
... University of Colorado Denver announced today that it will ... by the Bill & Melinda Gates Foundation that enables ... health and development challenges. Assistant Professor Zhiyong (Jason) ... Applied Science will pursue an innovative global health research ...
... (November 7, 2011) AMRI (NASDAQ: AMRI) announced today ... Eli Lilly and Company, it anticipates hiring more than ... to support Lilly,s drug discovery programs. The chemists will ... they will support the medicinal chemistry department. This ...
... -- ,Neuromuscular warm-ups may reduce knee injuries among female ... neuromuscular warm-up, an athlete begins with easy cardiovascular exercise ... in the sport. The study included 90 ... from public schools in Chicago. Half the coaches were ...
... have been going electronic, and patients, caregivers, and ... digital world of health information. Now three institutions ... populationpeople with disabilitiescan best access this information. ... Inglis Foundation, also based in Philadelphia, are partnering ...
... Hopkins Center for Injury Research and Policy finds fire ... comprehensive and coordinated approach to fire prevention. The study, ... fire service, highlights the diversity of prevention initiatives underway ... a sense of community are keys to success for ...
Cached Medicine News:Health News:CAMH study suggests increased risk of schizophrenia in heavy methamphetamine users 2Health News:Specialized Warm-Up May Reduce Girls' Knee Injuries 2Health News:Grant will help bridge digital divide for people with disabilities 2Health News:Grant will help bridge digital divide for people with disabilities 3Health News:Delaware Fire Service offers important lessons for fire prevention programs nationwide 2
... 6000 lets you manually ... precise positioning. The superior ... immediate and exact positioning ... making it especially effective ...
The Total Toe System offers a new generation in first metatarsophalangeal joint reconstruction....
The Acumed Great Toe System is a two-piece non-constrained implant for the first MP joint. The system was developed to provide ease of use for the surgeon, combined with precise instrumentation and a...
The design features of the Mini Lag Screw System simplify the screw fixation by reducing possible sources of error, reducing instrumentation, and decreasing the time of fixation....
Medicine Products: